Timing, fractionation, and dose of thoracic radiotherapy in patients with extensive-stage small cell lung cancer undergoing first-line Chemo-Immunotherapy | Synapse
March 3, 2026Open Access
Timing, fractionation, and dose of thoracic radiotherapy in patients with extensive-stage small cell lung cancer undergoing first-line Chemo-Immunotherapy
Key Points
Radiotherapy timing significantly influences treatment outcomes in extensive-stage small cell lung cancer, enhancing survival rates.
The study evaluates various dose fractionation schemes, with notable effects observed at specific intervals, indicating optimal scheduling.
Assessment using treatment models highlights the importance of timely radiotherapy combined with chemo-immunotherapy in clinical practice.
Findings may enable personalized treatment plans, emphasizing tailored therapy approaches based on radiotherapy timing.